+357 96 030922
info@marketpublishers.com

# U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, And Segment Forecasts, 2025 - 2033

https://marketpublishers.com/r/U1E954568C49EN.html
Date: August 2025
Pages: 120
Price: US$ 5,950.00 (Single User License)
ID: U1E954568C49EN

## Abstracts

U.S. Neurology Clinical Trials Market Summary

The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.

Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.

The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased

need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.

Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.

Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.

U.S. Neurology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, and value chain:

Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I

Phase II

Phase III

Phase IV

Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional

Observational

Expanded Access

Indication Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease

Depression (MDD)

Parkinson's Disease (PD)

Epilepsy

Stroke

Traumatic Brain Injury (TBI)

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Muscle Regeneration

Others

Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease

+357 96 030922
info@marketpublishers.com

- Interventional
- Observational
- Expanded Access

Depression (MDD)

- Interventional
- Observational
- Expanded Access

Parkinson's Disease (PD)

- Interventional
- Observational
- Expanded Access

Epilepsy

- Interventional
- Observational
- Expanded Access

Stroke

- Interventional
- Observational
- Expanded Access

+357 96 030922
info@marketpublishers.com

Traumatic Brain Injury (TBI)

- Interventional
- Observational
- Expanded Access

Amyotrophic Lateral Sclerosis (ALS)

- Interventional
- Observational
- Expanded Access

Huntington's Disease

- Interventional
- Observational
- Expanded Access

Muscle Regeneration

- Interventional
- Observational
- Expanded Access

Others

- Interventional
- Observational
- Expanded Access

+357 96 030922
info@marketpublishers.com

Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease

Phase I

Phase II

Phase III

Phase IV

Depression (MDD)

Phase I

Phase II

Phase III

Phase IV

Parkinson's Disease (PD)

Phase I

Phase II

Phase III

Phase IV

Epilepsy

Phase I

Phase II

+357 96 030922
info@marketpublishers.com

Phase III

Phase IV

Stroke

Phase I

Phase II

Phase III

Phase IV

Traumatic Brain Injury (TBI)

Phase I

Phase II

Phase III

Phase IV

Amyotrophic Lateral Sclerosis (ALS)

Phase I

Phase II

Phase III

Phase IV

Huntington's Disease

Phase I

Phase II

Phase III

Phase IV

Muscle Regeneration

Phase I

Phase II

Phase III

Phase IV

Others

Phase I

Phase II

Phase III

Phase IV

Value Chain Outlook (Revenue, USD Million, 2021 - 2033)

In-house

CROs

Investigator Sites/ Clinical Sites

**This report can be delivered to the clients within 2 Business Days**

+357 96 030922
info@marketpublishers.com

# Contents

## CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE



## CHAPTER 2. EXECUTIVE SUMMARY



## CHAPTER 3. U.S. NEUROLOGY CLINICAL TRIALS MARKET VARIABLES, TRENDS & SCOPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

## CHAPTER 9. U.S. NEUROLOGY CLINICAL TRIALS MARKET: VALUE CHAIN ESTIMATES & TREND ANALYSIS



## CHAPTER 10. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com


L

+357 96 030922
info@marketpublishers.com

# List Of Tables

## LIST OF TABLES

+357 96 030922
info@marketpublishers.com

## List Of Figures

### LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

## I would like to order

Product name: U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, And Segment Forecasts, 2025 - 2033

Product link: https://marketpublishers.com/r/U1E954568C49EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U1E954568C49EN.html